Alpha 2.0
Login Register
» Authors » Sebastian Cummins

Sebastian Cummins

Explore the profile of Sebastian Cummins including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 1094
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
Stephen Falk
Harpreet Wasan
Tom Crosby
Alec McDonald
Jonathan Wadsley
Markus W Buchler
Christopher M Halloran
David Cunningham
Thilo Hackert
Pascal Hammel
Published In
Eur Urol
JAMA Surg
Lancet Oncol
JAMA Oncol
Lancet
Affiliations
Soon will be listed here.
Recent Articles
1.
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Palmer D, Jackson R, Springfeld C, Ghaneh P, Rawcliffe C, Halloran C, et al.
J Clin Oncol . 2024 Dec; :JCO2401118. PMID: 39637340
Purpose: The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival...
2.
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial
Hall P, Swinson D, Cairns D, Waters J, Petty R, Allmark C, et al.
JAMA Oncol . 2021 May; 7(6):869-877. PMID: 33983395
Importance: Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap. Objective: The GO2 randomized clinical trial sought to optimize chemotherapy...
3.
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
Jones R, Psarelli E, Jackson R, Ghaneh P, Halloran C, Palmer D, et al.
JAMA Surg . 2019 Sep; 154(11):1038-1048. PMID: 31483448
Importance: The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective: To define patterns of recurrence after adjuvant chemotherapy and the association with...
4.
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
Neoptolemos J, Palmer D, Ghaneh P, Psarelli E, Valle J, Halloran C, et al.
Lancet . 2017 Jan; 389(10073):1011-1024. PMID: 28129987
Background: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic...
5.
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
Mukherjee S, Hurt C, Bridgewater J, Falk S, Cummins S, Wasan H, et al.
Lancet Oncol . 2013 Mar; 14(4):317-26. PMID: 23474363
Background: In the UK, chemotherapy is the standard treatment for inoperable, locally advanced, non-metastatic pancreatic cancer. Chemoradiotherapy is also an acceptable treatment option, for which gemcitabine, fluorouracil, or capecitabine can...
6.
Surveillance in stage I seminoma patients: a long-term assessment
Cummins S, Yau T, Huddart R, Dearnaley D, Horwich A
Eur Urol . 2009 Jun; 57(4):673-8. PMID: 19545941
Background: Following orchidectomy patients with stage I seminoma of the testis may be managed by either surveillance or adjuvant treatment. In view of the very high cure rate, it is...